Celltrion Past Earnings Performance
Past criteria checks 2/6
Celltrion has been growing earnings at an average annual rate of 1.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 14.5% per year. Celltrion's return on equity is 1.1%, and it has net margins of 6.5%.
Key information
1.6%
Earnings growth rate
0.4%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 14.5% |
Return on equity | 1.1% |
Net Margin | 6.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 22Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25Recent updates
Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 22Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
May 22Celltrion, Inc. (KRX:068270) Not Flying Under The Radar
Apr 30Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt
Mar 19Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock
May 05Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)
Mar 25Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like
Mar 15Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?
Feb 24Celltrion (KRX:068270) Has A Rock Solid Balance Sheet
Feb 03Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 13Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?
Dec 23Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?
Dec 02Revenue & Expenses Breakdown
How Celltrion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,876,253 | 187,097 | 762,997 | 161,112 |
30 Jun 24 | 2,666,611 | 323,331 | 610,011 | 161,112 |
31 Mar 24 | 2,315,848 | 392,826 | 407,846 | 161,112 |
31 Dec 23 | 2,176,432 | 535,648 | 198,356 | 161,112 |
30 Sep 23 | 2,304,473 | 603,795 | 196,472 | 139,714 |
30 Jun 23 | 2,277,818 | 542,616 | 179,966 | 139,714 |
31 Mar 23 | 2,350,070 | 582,780 | 183,631 | 139,714 |
31 Dec 22 | 2,283,967 | 526,616 | 204,971 | 139,714 |
30 Sep 22 | 2,376,733 | 566,168 | 220,603 | 125,769 |
30 Jun 22 | 2,133,015 | 543,369 | 217,022 | 125,769 |
31 Mar 22 | 1,967,894 | 482,930 | 194,374 | 125,769 |
31 Dec 21 | 1,893,401 | 569,488 | 180,730 | 125,769 |
30 Sep 21 | 1,788,695 | 564,777 | 175,444 | 171,437 |
30 Jun 21 | 1,935,547 | 597,615 | 167,273 | 171,437 |
31 Mar 21 | 1,933,237 | 608,477 | 150,937 | 171,437 |
31 Dec 20 | 1,849,116 | 517,760 | 126,626 | 171,437 |
30 Sep 20 | 1,733,144 | 512,182 | 148,229 | 113,568 |
30 Jun 20 | 1,473,428 | 402,929 | 140,896 | 113,568 |
31 Mar 20 | 1,279,603 | 342,041 | 141,114 | 113,568 |
31 Dec 19 | 1,128,460 | 301,030 | 131,592 | 113,568 |
30 Sep 19 | 988,284 | 230,443 | 144,915 | 108,060 |
30 Jun 19 | 930,333 | 225,180 | 131,754 | 108,060 |
31 Mar 19 | 958,797 | 228,480 | 126,670 | 108,060 |
31 Dec 18 | 982,075 | 245,755 | 113,897 | 108,060 |
30 Sep 18 | 1,013,790 | 308,254 | 132,375 | 79,660 |
30 Jun 18 | 1,014,774 | 355,009 | 131,874 | 79,660 |
31 Mar 18 | 997,483 | 381,655 | 125,612 | 79,660 |
31 Dec 17 | 949,080 | 368,222 | 112,701 | 79,660 |
30 Sep 17 | 883,631 | 308,461 | 94,727 | 87,856 |
30 Jun 17 | 819,814 | 263,666 | 78,505 | 87,856 |
31 Mar 17 | 758,701 | 215,812 | 65,778 | 87,856 |
31 Dec 16 | 670,581 | 158,958 | 75,517 | 87,856 |
30 Sep 16 | 630,045 | 176,699 | 96,722 | 37,320 |
30 Jun 16 | 631,225 | 181,015 | 88,835 | 37,320 |
31 Mar 16 | 614,243 | 179,605 | 84,306 | 37,320 |
31 Dec 15 | 603,413 | 154,090 | 66,696 | 37,320 |
30 Sep 15 | 534,991 | 117,389 | 44,620 | 69,642 |
30 Jun 15 | 470,682 | 70,144 | 52,551 | 69,642 |
31 Mar 15 | 481,797 | 84,083 | 66,040 | 69,642 |
31 Dec 14 | 471,046 | 112,676 | 64,767 | 69,642 |
30 Sep 14 | 373,936 | 97,604 | 82,928 | 25,386 |
30 Jun 14 | 349,650 | 118,987 | 62,678 | 25,386 |
31 Mar 14 | 232,292 | 83,007 | 39,321 | 17,804 |
31 Dec 13 | 226,208 | 102,455 | 25,241 | 25,386 |
Quality Earnings: A068270 has high quality earnings.
Growing Profit Margin: A068270's current net profit margins (6.5%) are lower than last year (26.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A068270's earnings have grown by 1.6% per year over the past 5 years.
Accelerating Growth: A068270's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A068270 had negative earnings growth (-69%) over the past year, making it difficult to compare to the Biotechs industry average (7.9%).
Return on Equity
High ROE: A068270's Return on Equity (1.1%) is considered low.